Protective Effect of Indocyanine Green Fluorescence Imaging Technology on Parathyroid Glands During Total Thyroidectomy
Launched by SHANDONG LINGLONG YINGCHENG HOSPITAL · Feb 25, 2024
Trial Information
Current as of September 08, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to help protect the parathyroid glands during a surgery called total thyroidectomy, which is the removal of the thyroid gland. The researchers want to find out if using a special imaging technique, called indocyanine green fluorescence imaging, along with another method called autofluorescence, can help doctors better see and evaluate the parathyroid glands during surgery. This approach aims to reduce the risk of a condition called hypoparathyroidism, which can occur after surgery and affects calcium levels in the body.
To participate in this trial, you need to be an adult aged 18 or older who is scheduled for thyroid surgery. You should have normal liver and kidney function and not have any allergies to indocyanine green or iodine. If you join the study, you can expect to undergo the standard procedures for thyroid surgery, with additional imaging techniques to help protect your parathyroid glands. The study is currently recruiting participants, and it’s important that you understand the study process and are willing to give your consent to participate.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female patients, aged 18 years and above
- • Scheduled for elective total or hemi thyroidectomy
- • Normal liver and renal function
- • No known hypersensitivity for iodine or ICG
- • Able to understand the nature of the study procedures
- • Willing to participate and give written informed consent
- Exclusion Criteria:
- • Age \< 18 years
- • Liver or renal insufficiency
- • Known ICG, iodine, penicillin or sulfa hypersensitivity
- • Pregnancy or breastfeeding
- • Not able to understand the nature of the study procedure
- • Not willing to participate
About Shandong Linglong Yingcheng Hospital
Shandong Linglong Yingcheng Hospital is a leading healthcare institution committed to advancing medical research and patient care through innovative clinical trials. Recognized for its state-of-the-art facilities and a multidisciplinary team of experienced professionals, the hospital focuses on a wide range of therapeutic areas, aiming to enhance treatment outcomes and improve quality of life for patients. With a dedication to ethical standards and regulatory compliance, Shandong Linglong Yingcheng Hospital actively collaborates with researchers and industry partners to contribute to the development of new therapies and medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Yantai, Shandong, China
Patients applied
Trial Officials
Xuan Qiu, MD
Principal Investigator
Shandong Linglong Yingcheng Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported